PL3925966T3 - Nowa krystaliczna postać związku blokującego przeciek naczyniowy - Google Patents
Nowa krystaliczna postać związku blokującego przeciek naczyniowyInfo
- Publication number
- PL3925966T3 PL3925966T3 PL20908441.7T PL20908441T PL3925966T3 PL 3925966 T3 PL3925966 T3 PL 3925966T3 PL 20908441 T PL20908441 T PL 20908441T PL 3925966 T3 PL3925966 T3 PL 3925966T3
- Authority
- PL
- Poland
- Prior art keywords
- crystalline form
- novel crystalline
- vascular leakage
- blocker compound
- leakage blocker
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J67/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of two rings, each by one atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J17/005—Glycosides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
- C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020200053232A KR102223276B1 (ko) | 2020-05-04 | 2020-05-04 | 혈관 누출 차단제 화합물의 신규 결정형 |
| PCT/KR2020/013505 WO2021225233A1 (ko) | 2020-05-04 | 2020-10-05 | 혈관 누출 차단제 화합물의 신규 결정형 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3925966T3 true PL3925966T3 (pl) | 2025-03-31 |
Family
ID=78414795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20908441.7T PL3925966T3 (pl) | 2020-05-04 | 2020-10-05 | Nowa krystaliczna postać związku blokującego przeciek naczyniowy |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12103945B2 (pl) |
| JP (1) | JP7220931B2 (pl) |
| CN (1) | CN113906041B (pl) |
| BR (1) | BR112021020382A2 (pl) |
| CA (1) | CA3133441C (pl) |
| ES (1) | ES3001563T3 (pl) |
| HR (1) | HRP20250033T8 (pl) |
| IL (1) | IL292452A (pl) |
| MX (1) | MX2021013884A (pl) |
| PL (1) | PL3925966T3 (pl) |
| RS (1) | RS66468B1 (pl) |
| SA (1) | SA521430863B1 (pl) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101293278B1 (ko) | 2009-10-29 | 2013-08-09 | 주식회사 한독 | 신규 혈관누출 차단제 |
| CN105949264A (zh) * | 2012-04-01 | 2016-09-21 | 浙江海正药业股份有限公司 | 人参皂苷c-k的两种晶型及其制备方法 |
| KR101481709B1 (ko) | 2014-01-03 | 2015-02-02 | 인하대학교 산학협력단 | Sac-1004 복합체를 유효성분으로 포함하는 발기부전 예방 또는 치료용 조성물 |
| US20220152067A1 (en) * | 2019-04-29 | 2022-05-19 | lndustry-Academic Cooperation Foundation, Yonsei University | Cancer Immunotherapy Adjuvant |
| KR102124470B1 (ko) * | 2019-12-13 | 2020-06-18 | 주식회사 큐라클 | 신규 혈관누출 차단제의 고수율 제조방법 |
-
2020
- 2020-10-05 US US17/421,165 patent/US12103945B2/en active Active
- 2020-10-05 CN CN202080010768.0A patent/CN113906041B/zh active Active
- 2020-10-05 BR BR112021020382A patent/BR112021020382A2/pt unknown
- 2020-10-05 PL PL20908441.7T patent/PL3925966T3/pl unknown
- 2020-10-05 HR HRP20250033TT patent/HRP20250033T8/hr unknown
- 2020-10-05 JP JP2021542132A patent/JP7220931B2/ja active Active
- 2020-10-05 IL IL292452A patent/IL292452A/en unknown
- 2020-10-05 ES ES20908441T patent/ES3001563T3/es active Active
- 2020-10-05 RS RS20250048A patent/RS66468B1/sr unknown
- 2020-10-05 CA CA3133441A patent/CA3133441C/en active Active
- 2020-10-05 MX MX2021013884A patent/MX2021013884A/es unknown
-
2021
- 2021-11-15 SA SA521430863A patent/SA521430863B1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES3001563T3 (en) | 2025-03-05 |
| CA3133441A1 (en) | 2021-11-04 |
| HRP20250033T1 (hr) | 2025-03-14 |
| US12103945B2 (en) | 2024-10-01 |
| CN113906041B (zh) | 2025-01-14 |
| JP2022525582A (ja) | 2022-05-18 |
| SA521430863B1 (ar) | 2024-04-16 |
| MX2021013884A (es) | 2021-12-14 |
| HRP20250033T8 (hr) | 2025-11-07 |
| BR112021020382A2 (pt) | 2023-01-17 |
| JP7220931B2 (ja) | 2023-02-13 |
| IL292452A (en) | 2022-06-01 |
| RS66468B1 (sr) | 2025-03-31 |
| CA3133441C (en) | 2023-01-03 |
| US20220259256A1 (en) | 2022-08-18 |
| CN113906041A (zh) | 2022-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL316075A (en) | Crystalline form of lenifranor | |
| IL304159A (en) | A preparation containing bl-8040 | |
| GB202102360D0 (en) | Crystalline compound | |
| HUE070010T2 (hu) | Vaszkuláris szivárgást gátló vegyület új kristályformája | |
| ES3049298T3 (en) | Solid form of compound | |
| EP4067360A4 (en) | CRYSTALLINE FORM OF A NITROGEN-CONTAINING TRICYCLIC COMPOUND AND ITS USE | |
| PL3925966T3 (pl) | Nowa krystaliczna postać związku blokującego przeciek naczyniowy | |
| PL3854800T3 (pl) | Wysokowydajny sposób wytwarzania nowego blokera przecieku naczyniowego | |
| GB202302314D0 (en) | Compound | |
| GB202301239D0 (en) | Compound | |
| GB202216325D0 (en) | Compound | |
| EP4144734A4 (en) | APPLICATION OF A HETEROCYCLIC COMPOUND | |
| GB202314158D0 (en) | Inhibition of vascular leakage | |
| GB202110544D0 (en) | Inhibition of vascular leakage | |
| HK40086627B (zh) | 酞嗪酮化合物的结晶形式 | |
| GB202311665D0 (en) | Modification of composition | |
| GB202217726D0 (en) | Crystalline compound | |
| HK40097048A (zh) | 新的多酚化合物 | |
| HK40097048B (zh) | 新的多酚化合物 | |
| HK40120719A (zh) | 拉尼兰诺的晶型 | |
| HK40096047A (en) | Crystalline form of aspacytarabine | |
| HK40082031A (en) | Crystalline form of lnp023 | |
| HK40087466A (en) | Crystal form of azetidine-substituted compound | |
| CA3266364A1 (en) | Use of heteroaryloxynaphthalene compound | |
| HK40116601A (en) | Crystalline form of lanifibranor |